Milos boy receives gene therapy, his wounds heal faster

LokalecIndependentCenter6 hr. ago

A three-year-old boy named Miloš has begun receiving genetic treatment with the drug Vyjuvek at the University Clinical Center Ljubljana (UKC). The treatment, which is applied in gel form, aims to accelerate wound healing. After three applications, medical staff observed faster healing at treated sites compared to untreated areas. Miloš suffers from a rare genetic condition called bullous epidermolysis, which causes chronic blistering and wounds throughout his body. His condition is severe, affecting large skin areas, and current treatments are limited. While Vyjuvek is already used in the U.S., it is now being tested in Slovenia. Doctors emphasize that this is not a cure but rather long-term management, requiring ongoing application. They hope the treatment could benefit other patients with similar conditions in the future.

Bias read (Center): The article presents factual information about a medical treatment without overt ideological framing. It focuses on clinical observations and expert commentary, maintaining neutrality by avoiding value judgments or partisan perspectives. The emphasis is on scientific process and patient care rather

N1 SlovenijaIndependentCenter7 hr. ago

A 9-year-old boy named Miloš has received gene therapy at the University Clinical Center Ljubljana (UKC), making him the first child in Slovenia to undergo this treatment for bullous epidermolysis vulgaris, a severe genetic skin condition. The therapy, called Vyjuvek, is applied weekly and has shown early signs of effectiveness, with wounds healing faster in treated areas compared to untreated regions. The treatment requires lifelong administration, as the condition causes chronic blistering and wounds throughout life. While the therapy is costly and previously available only in the U.S., it is now accessible in Slovenia through health insurance. Doctors emphasize that while the therapy is promising, long-term effects and comparisons with other treatments require further observation over weeks or months. The case highlights potential future applications of gene therapy for similar conditions in Slovenia.

Bias read (Center): The article presents factual medical information about a specific patient receiving a new treatment, without overt ideological framing. It focuses on healthcare advancements and clinical outcomes rather than political debate or advocacy. While the topic relates to public policy (healthcare access),

DnevnikIndependent🔒Center7 hr. ago

A Slovenian child named Miloš has received a new gene therapy called Vyjuvek at the University Clinical Center Ljubljana, showing positive effects after three applications. The treatment, which is applied in gel form, helps accelerate wound healing compared to areas where the medication is not administered. Miloš suffers from a rare genetic condition known as bullous epidermolysis, causing chronic blisters and wounds throughout his body. The therapy is costly and previously used in the US by the Slovenian Health Insurance Fund. While the treatment does not cure the condition, it offers long-term management, allowing Miloš to receive care for his wounds over time. Doctors emphasize that this is not a curative gene therapy but rather a lifelong treatment. This case highlights the potential of advanced therapies for rare diseases, though broader access remains limited.

Bias read (Center): The article presents a factual medical update on a specific patient receiving a novel treatment, focusing on clinical outcomes and expert commentary. There is no overt ideological framing, partisan emphasis, or biased language. The narrative remains objective, centered on medical progress and health